



# NATIONAL INFLUENZA VACCINE SUMMIT NEWSLETTER

October 2006  
Issue 4

---

## IN THIS ISSUE

(Click on any of the following links to go directly to the page displaying the article.)

- [National Influenza Vaccination Week – November 27<sup>th</sup> to December 3<sup>rd</sup>](#)
- [FluLaval licensed! Up to 115 million total doses now projected](#)
- [Where can healthcare providers buy vaccine? Try IVATS!](#)
- [Having issues with or questions about this season’s vaccine distribution?](#)
- [NFID Convenes National News Conference to kick off flu season](#)
- [HIDA developing Code of Responsible Business Practices for their vaccine distributors](#)
- [Free advertising for your influenza clinics](#)
- [AMA/AAP Immunization Initiatives meeting date changed](#)
- [2006-2007 ACIP recommendations for prevention and control of influenza](#)
  - [Changes from 2005-2006 ACIP recommendations](#)
- [ACIP recommendations for healthcare workers](#)
- [Details about this season’s vaccine \(now including FluLaval<sup>TM</sup>\)](#)
- [Influenza resources and events](#)
  - [What’s New?](#)
  - [Upcoming Events](#)
  - [How do I subscribe to this newsletter?](#)
  - [How do I access previous issues of this newsletter?](#)
  - [Comments and suggestions for this newsletter?](#)

---

## NATIONAL INFLUENZA VACCINATION WEEK - November 27<sup>th</sup> to December 3<sup>rd</sup>

To help raise awareness of influenza vaccination recommendations and the importance of continuing vaccination efforts throughout November and beyond, the United States Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention (CDC), the National Influenza Vaccine Summit, partners and stakeholders will be announcing a National Influenza Vaccination Week (NIVW) from Monday, November 27<sup>th</sup> through Sunday, December 3<sup>rd</sup>, 2006.

Although a press event will be held November 13<sup>th</sup> to announce NIVW, in order not to preempt this event, please consider the information in this email embargoed until after the event has occurred. Other national events are being planned for the actual week. Partners may use this opportunity to help plan vaccination clinics and flu vaccine promotion activities with providers, state and local health departments, mass vaccinators, retail vaccinators, and other healthcare organizations. We encourage you to foster your own creative ideas with your vaccination campaign, whether it’s working at a local level with business groups, religious groups, supermarkets, worksite employers, senior centers, or other community groups. Free materials are available for easy printing at CDC’s “flu gallery” [www.cdc.gov/flu/gallery](http://www.cdc.gov/flu/gallery), including posters, flyers, and educational handouts. More materials specific to this event soon will be available.

[\(Back to top\)](#)

## **FLULAVAL™ LICENSED! UP TO 115 MILLION TOTAL DOSES NOW PROJECTED**

The U.S. Food and Drug Administration (FDA) has approved FLULAVAL™ [trivalent inactivated influenza virus vaccine] for the immunization of adults 18 years and older (FLULAVAL™ is not indicated for use in children.). The approval of FLULAVAL™ is another major step towards increasing the influenza vaccine supply in the United States. GSK added FLULAVAL™ to its portfolio of flu products when it acquired the Canadian vaccine manufacturer ID Biomedical Corporation in December 2005. FLULAVAL™ is available in multi-dose vials (10 doses per vial). This vaccine is marketed in Canada under the name Fluviral®.

[\(Back to top\)](#)

## **WHERE CAN HEALTHCARE PROVIDERS BUY VACCINE? TRY IVATS!**

A record number of up to 115 million doses of influenza vaccine are expected for the 2006-2007 influenza season, with 62.5 million doses reported as distributed by October 27<sup>th</sup>.

Frequently throughout every vaccination season, healthcare providers and facilities ask where they can obtain influenza vaccine. With no current information available regarding who has vaccine to sell, the answer usually is to “call a distributor or manufacturer.”

To address this need, the Summit has developed the Influenza Vaccine Availability Tracking System, or IVATS. The goal of IVATS is to establish a voluntary, centralized, regularly updated national resource that health care providers can access to learn: 1) which distributors have influenza vaccine for sale; and 2) how to contact and order vaccine from these distributors. The Health Industry Distributor Association actively recruited their member distributors and Healthcare Distribution Management Association (HDMA) notified their distributor members.

Please note that all information is provided by distributors on a voluntary basis and is not intended to endorse or promote one distributor's or manufacturer's product over another, and all distributors are welcome and encouraged to enroll in IVATS. Also note that primary purpose of IVATS is to offer healthcare providers regularly updated vaccine availability data, not to be confused with CDC's influenza vaccine distribution tracking system which provides confidential distribution data by zip code. The CDC distribution data is available only to officials designated by state health departments through a secure data network.

The Summit will host on their website a spreadsheet listing participating distributors with influenza vaccine for sale. This listing will be updated with new information every other week throughout the influenza season.

### **Influenza vaccine distributors**

If you would like to learn more about IVATS, enroll, and submit your first report, please take these steps.

1. Go to Summit website at: [www.ama-assn.org/go/influenzasummit](http://www.ama-assn.org/go/influenzasummit)
2. Click: **The Summit's Influenza Vaccine Availability Tracking System (IVATS)**.
3. Click: **For Influenza Vaccine Distributors – How do I enroll?**
4. Click: **1. Go to the Summit's IVATS enrollment page**.
5. Scroll down to the enrollment section of this page and enter the requested information.
6. Click red box at end of form in lower right corner: **Submit form >**

7. On next screen, click “**click here to continue**” to return to the enrollment page.
8. Click **IVATS bi-weekly reporting page**.
9. Scroll down, complete your first Report and click **Submit** in lower left corner.

### **Healthcare providers**

If you would like to access the spreadsheet to identify distributors with influenza vaccine for sale, please take these steps.

1. Go to Summit website at: [www.ama-assn.org/go/influenzasummit](http://www.ama-assn.org/go/influenzasummit)
  2. Click: **The Summit’s Influenza Vaccine Availability Tracking System (IVATS)**.
  3. Click: **For Healthcare Providers – Who has influenza vaccine for sale?**
  4. A spreadsheet will appear with this information.
- **As of October 31<sup>st</sup>, 9 distributors have enrolled and 4 have submitted their first report.**

[\(Back to top\)](#)

## **HAVING ISSUES WITH OR QUESTIONS ABOUT THIS SEASON’S VACCINE DISTRIBUTION?**

To read the article on the CDC website, click on the following link.

<http://www.cdc.gov/flu/professionals/vaccination/cdcletter2006oct.htm>

[\(Back to top\)](#)

## **NFID CONVENES NATIONAL NEWS CONFERENCE TO KICK OFF FLU SEASON**

The National Foundation for Infectious Diseases (NFID) recently partnered with the National Influenza Vaccine Summit and many of the nation’s leading infectious disease experts to convene its Annual Influenza/Pneumococcal Disease News Conference to urge influenza vaccination throughout the fall and winter.

The following experts served on the panel for the news conference, held at the National Press Club in Washington, D.C., on October 4:

- Julie L. Gerberding, MD, MPH, CDC Director
- Mark B. McClellan, MD, PhD, CMS Administrator
- Daniel B. Jernigan, MD, MPH, Deputy Director, CDC Influenza Division
- William G. Plested, III, MD, AMA President
- Julia A. McMillan, MD, FAAP, AAP Committee on Infectious Diseases
- Susan J. Rehm, MD, NFID Medical Director
- William Schaffner, MD, NFID Vice President

Panelists reinforced there will be ample influenza vaccine supply for the 2006-2007 season, reviewed this year’s immunization recommendations and the need to vaccinate into December, January and later, and discussed the importance of pneumococcal vaccination for people 65 years of age and older and those with chronic health conditions. The event secured extensive media attendance and coverage from numerous outlets across the country, including Associated Press, Reuters, CNN Headline News, MSNBC, CBS Early Show, *USA Today*, *Newsday*, *Miami Herald*, *American Medical News*, among others nationwide.

NFID also released results of a recent national consumer survey of public perceptions about influenza vaccination and treatment, reinforcing the need for ongoing education, especially using the media to help inform Americans. Alarming, nearly half of respondents did not plan to be immunized against influenza this year, and many Americans did not recognize the severity of influenza for themselves and their loved ones. Almost half did not know vaccination is still beneficial into December and beyond.

An archived Web cast of the News Conference and additional resources are available for ongoing access via NFID's Web site: [www.nfid.org](http://www.nfid.org).

[\(Back to top\)](#)

## **HIDA DEVELOPING CODE OF RESPONSIBLE BUSINESS PRACTICES FOR THEIR VACCINE DISTRIBUTORS**

The Health Industry Distributors Association (HIDA), a regular and valued partner in the Summit, is developing a voluntary Code of Responsible Business Practices for distributors of seasonal influenza vaccine. The voluntary Code, which is part of HIDA's Flu Vaccine Business Practices Initiative, is being developed to educate customers and relevant stakeholders and to highlight distributors' commitment to responsible business practices. This code outlines several key tenets including: member compliance with CDC goals and guidelines, a forum to address and assess flu vaccine distribution grievances, and more. For additional information about the Code, visit <http://www.flusupplynews.com/code.cfm>. For more information on the Flu Vaccine Business Practices Initiative, visit <http://www.flusupplynews.com/index.cfm>.

[\(Back to top\)](#)

## **FREE ADVERTISING FOR YOUR INFLUENZA CLINICS**

The American Lung Association (ALA) and Maxim Health Systems continue to offer their national Flu Clinic Locator for both influenza clinics and for persons seeking a vaccination.

### **Healthcare providers interested in advertising their clinics**

Registration is required and training available to healthcare administrators interested in becoming site administrators for your influenza clinics. To start this process, you will need to sign an updated agreement designed to ensure a successful outcome. This agreement requires each administrator to: 1) keep all posted clinic information up-to-date; 2) follow CDC guidelines in managing your clinics; and 3) post only clinics that are open to the public. If your organization can commit to all three requirements, read the full Flu Clinic Locator Agreement at [www.lungusa2.org/embargo/flucliniclocator/FCLAgreement0806.doc](http://www.lungusa2.org/embargo/flucliniclocator/FCLAgreement0806.doc). If you wish to enroll, first print the form, fill in the blanks, sign, date, and fax to (212) 315-8870.

### **Persons seeking an influenza vaccination**

The public may find influenza clinics in their areas by visiting the Flu Clinic Locator at [www.flucliniclocator.org](http://www.flucliniclocator.org).

[\(Back to top\)](#)

## **AMA/AAP IMMUNIZATION INITIATIVES MEETING DATE CHANGED**

**The AAP and AMA have agreed to co-host this three-day meeting on adult and pediatric immunization which will convene in Chicago from Tuesday February 27<sup>th</sup> through Wednesday March 1, 2007. If interested in attending, please “save these dates.”**

The pediatric session will occupy the first day. A transition session will link common issues on the morning of the second day and will be followed by the adult session for the rest of the meeting.

### **The American Medical Association (AMA)**

Adult immunization and influenza represent an important AMA strategic initiative. Four objectives have been identified for an Adult Immunization Summit:

- 1) improving the valuation of adult immunization;
- 2) improving the vaccine delivery infrastructure;
- 3) facilitating healthcare providers to immunize adult patients; and
- 4) addressing vaccine financing.

Some tangible first steps have been developed to address these objectives and achieve improvement in adult immunization coverage.

### **The American Academy of Pediatrics (AAP)**

Immunization also is a strategic priority for the AAP which recently formed a Task Force on Immunization which established the following three priorities:

- 1) to increase the number of children receiving vaccines in the medical home;
- 2) to stabilize the vaccine supply chain; and
- 3) to improve the current vaccine finance system.

With the introduction of new vaccines that carry a considerable price tag, the Task Force feels the time is right for a Pediatric Immunization Key Stakeholder Meeting.

### **The Joint Meeting**

As more adolescent and adult vaccines such as HPV enter the market, the traditionally separate concerns of pediatric and adult immunizations are becoming increasingly similar. The AMA and AAP believe this is an opportune time to come together, understand each other's concerns, and define some areas of common interest for action. Thus, it has been decided to combine into one three-day event the AMA's Adult Immunization Summit and the AAP's Pediatric Immunization Key Stakeholder Meeting. The AAP and AMA have identified many stakeholders who have interest in both adult and pediatric immunization and hope this combined event will facilitate the stakeholders' participation in both meetings. The uniting of these two important immunization gatherings will facilitate dialogue and exchange of ideas, concerns, etc. Additional details about the meeting (hotel, etc.) will be forthcoming in a future National Influenza Vaccine Summit Newsletter.

[\(Back to top\)](#)

## 2006-2007 ACIP RECOMMENDATIONS FOR PREVENTION AND CONTROL OF INFLUENZA

“**Prevention and Control of Influenza**, Recommendations of the Advisory Committee on Immunization Practices (ACIP),” MMWR **July 28, 2006**; 55(RR10); 1–42  
[www.cdc.gov/mmwr/preview/mmwrhtml/rr5510a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5510a1.htm)

[\(Back to top\)](#)

## CHANGES FROM 2005-2006 ACIP RECOMMENDATIONS

To view the primary changes made since the 2005-2006 recommendations, please click on the following link. [www.cdc.gov/flu/professionals/vaccination/primarychanges.htm](http://www.cdc.gov/flu/professionals/vaccination/primarychanges.htm)

[\(Back to top\)](#)

## ACIP RECOMMENDATIONS FOR HEALTHCARE WORKERS

“**Influenza Vaccination of Health-Care Personnel**, Recommendations of the Health care Infection Control Practices Advisory Committee (HICPAC) and the Advisory Committee on Immunization Practices (ACIP),” MMWR **February 24, 2006**; 55(RR02); 1–16  
[www.cdc.gov/mmwr/preview/mmwrhtml/rr5502a1.htm](http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5502a1.htm)

[\(Back to top\)](#)

## DETAILS ABOUT THIS SEASON’S VACCINE (NOW INCLUDING FluLaval™)

Manufacturer	Vaccine	Formulation	Thimerosal preservative	Age indication
sanofi pasteur, Inc.	Fluzone®, Inactivated TIV	Multi-dose vial	Yes	≥ 6 months
		Single-dose pre-filled 0.5 mL syringe or vial	None	≥ 36 months
		Single-dose pre-filled 0.25 mL syringe	None	6-35 months
MedImmune Vaccines, Inc	FluMist™ LAIV	Single-dose sprayer	None	Healthy persons 5-49 years
Novartis Vaccine (formerly Chiron Corporation)	Fluvirin™ Inactivated TIV	Multi-dose vial	Yes	≥ 4 years
GlaxoSmithKline, Inc.	Fluarix™ Inactivated TIV	Single-dose pre-filled syringe 0.5 mL	<1µg Hg/0.5mL dose, preservative free	≥ 18 years
GlaxoSmithKline, Inc.	FLULAVAL™ Inactivated TIV	Multi-dose vials	Yes	≥ 18 years

[\(Back to top\)](#)

## INFLUENZA RESOURCES & EVENTS

### What's New?

This page lists all documents recently posted or updated on the CDC Flu web site, including but not limited to press releases, ACIP recommendations, and surveillance reports.

[www.cdc.gov/flu/whatsnew.htm](http://www.cdc.gov/flu/whatsnew.htm)

### Upcoming Events

Adult/Pediatric Vaccine Summit, February 27 - March 1, 2007, Chicago, Illinois

Location and registration information will be available in a future Newsletter.

### How do I subscribe to this newsletter?

1. Send an e-mail message to [LISTSERV@LISTSERV.CDC.GOV](mailto:LISTSERV@LISTSERV.CDC.GOV)
2. Within the **body** of the message type the following: SUBSCRIBE FLU-SERVE
3. **Make sure there is nothing in the subject line**
4. Make sure there is absolutely nothing else in the body of the message; this include spaces, signatures, names, address, notes, etc.
5. You'll receive an e-mail message as a confirmation.

You will receive upcoming issues of this newsletter as well as other information or announcements pertaining to influenza and adult immunization.

### How do I access previous issues of this newsletter?

Previous issues of National Influenza Vaccine Summit Newsletters are available on the CDC website at [www.cdc.gov/flu/professionals/flubulletin.htm](http://www.cdc.gov/flu/professionals/flubulletin.htm) and on the Summit website at [www.ama-assn.org/go/influenzasummit](http://www.ama-assn.org/go/influenzasummit).

### Comments and suggestions for this newsletter?

[jrh3@cdc.gov](mailto:jrh3@cdc.gov)

[\(Back to top\)](#)

---

*The National Influenza Vaccine Summit is co-sponsored by the AMA and CDC. Materials published in this Newsletter are provided by a variety of sources and should not be misconstrued to represent CDC or AMA policy unless otherwise stated.*